Pre‐referral rectal artesunate probably leads to lower all cause mortality compared with placebo (moderate certainty).
Pre‐referral rectal artesunate showed no clear difference in neurodisability compared with placebo (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 28 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in total failure: day 42 (PCR‐adjusted) compared with artemether‐lumefantrine (AL) (low certainty).
The review found no eligible studies for this question.
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events compared with other antimalarials (moderate certainty).
Pyronaridine‐artesunate (PY‐AS) leads to higher first treatment, abnormal ALT increase compared with other antimalarials (high certainty).
Pyronaridine‐artesunate (PY‐AS) probably leads to higher first treatment, abnormal AST increase compared with other antimalarials (moderate certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase compared with other antimalarials (moderate certainty).
Pyronaridine‐artesunate (PY‐AS) may leads to lower total failure: day 28 (unadjusted) compared with artemether‐lumefantrine (AL) (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal ALT increase compared with other antimalarials (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal AST increase compared with other antimalarials (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in subsequent treatment(s), abnormal bilirubin increase compared with other antimalarials (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal ALT increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
Pyronaridine‐artesunate (PY‐AS) may leads to higher first treatment, abnormal AST increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in first treatment, abnormal bilirubin increase (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
Praziquantel and artesunate may leads to lower parasitological failure at 8 weeks compared with praziquantel (low certainty).
Praziquantel and artesunate showed no clear difference in microhaematuria compared with praziquantel (low certainty).